Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Apr;11(2):299-301.
doi: 10.21037/hbsn-21-548.

Metabolic dysfunction-associated fatty liver disease (MAFLD) and non-alcoholic fatty liver disease (NAFLD): distinct fatty liver entities with different clinical outcomes?

Eda Kaya  1   2 , Aleko Zedginidze  1   2 , Lars Bechmann  1   2 , Ali Canbay  1   2
Affiliations
Editorial

Metabolic dysfunction-associated fatty liver disease (MAFLD) and non-alcoholic fatty liver disease (NAFLD): distinct fatty liver entities with different clinical outcomes?

Eda Kaya et al. Hepatobiliary Surg Nutr. 2022 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-21-548/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020;73:202-9. 10.1016/j.jhep.2020.03.039 - DOI - PubMed
    1. Yilmaz Y, Byrne CD, Musso G. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol 2021;15:345-52. 10.1080/17474124.2021.1860019 - DOI - PubMed
    1. Kim D, Konyn P, Sandhu KK, et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol 2021;75:1284-91. 10.1016/j.jhep.2021.07.035 - DOI - PubMed
    1. Lim GEH, Tang A, Ng CH, et al. An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. Clin Gastroenterol Hepatol 2021. [Epub ahead of print]. doi: .10.1016/j.cgh.2021.11.038 - DOI - PubMed
    1. Yamamura S, Eslam M, Kawaguchi T, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int 2020;40:3018-30. 10.1111/liv.14675 - DOI - PubMed